FT. LAUDERDALE, Fla.–(BUSINESS WIRE)–Trividia Health, Inc., announced today that it is initiating a labeling correction which requires a modification of the OwnerFT. LAUDERDALE, Fla.–(BUSINESS WIRE)–Trividia Health, Inc., announced today that it is initiating a labeling correction which requires a modification of the Owner

Trividia Health, Inc. Initiates Labeling Correction for all TRUE METRIX® Blood Glucose Monitoring Systems

2026/02/07 02:15
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

FT. LAUDERDALE, Fla.–(BUSINESS WIRE)–Trividia Health, Inc., announced today that it is initiating a labeling correction which requires a modification of the Owner’s Booklets/System Instructions for Use for all TRUE METRIX, TRUE METRIX AIR, TRUE METRIX GO, and TRUE METRIX PRO Blood Glucose Monitoring Systems (collectively, the “Products”) distributed in the United States, United Kingdom, Mexico, Australia, and the Caribbean.

Trividia is updating the E-5 Error Code in the “Messages” section of the Owner’s Booklets/System Instructions for Use to emphasize that users must seek medical attention immediately if they receive an E-5 error code and are experiencing symptoms of high glucose.

The system displays an E-5 error code for a very high blood glucose event (> 600 mg/dL) or when there is a test strip error. As currently written, the instructions could potentially lead to a delay in treatment if the user does not seek medical attention immediately when they receive an E-5 error code and are experiencing symptoms of high glucose. A delay in treatment may result in serious adverse health consequences or death, especially for users with very high blood glucose levels.

Since August 2014, when TRUE METRIX was launched globally, there have been 114 reported serious injuries, and one (1) death associated with the E-5 Error Code.

UPDATED E-5 INSTRUCTIONS for TRUE METRIX, TRUE METRIX AIR, and TRUE METRIX GO:

Display

Reason

Action

E-5

Very high blood glucose result (higher than 600 mg/dL),

or Test Strip Error

WARNING!!

Retest with a new test strip.

If the error persists and you have symptoms such as fatigue, excess urination, thirst or blurry vision, seek medical attention immediately.

If you are not experiencing symptoms, retest with a new test strip. If the error persists, call 1-800-803-6025, Monday – Friday, 8AM-8PM EST for assistance.

UPDATED E-5 INSTRUCTIONS for TRUE METRIX PRO:

Display

Reason

Action

E-5

Very high blood glucose result (higher than 600 mg/dL),

or Test Strip Error

WARNING!!

Retest with a new test strip.

If the error persists, and the patient has symptoms such as fatigue, excess urination, thirst or blurry vision, seek medical attention immediately.

If the patient has no symptoms, retest with a new test strip. If the error persists, call 1-800-803-6025, Monday – Friday, 8AM-8PM EST for assistance.

If you have any questions relating to the Owner’s Booklets/System Instructions for Use update, please call Trividia Health Customer Care Department toll-free at 1-888-835-2723 Monday-Friday 8AM-8PM EST (excluding holidays) or e-mail trividia0126CC@trividiahealth.com or visit www.trividiahealth.com/E-5productnotice.

The correction affects all TRUE METRIX branded Blood Glucose Meters distributed in the United States, United Kingdom, Mexico, Australia and the Caribbean. This includes our co-branded products sold under store or distribution partner names. Please refer to the Product Notice located at www.trividiahealth.com/E-5productnotice for more information on the list of co-brand partners and affected product labeling.

The company is sending the Product Notice to impacted customers with instructions on what to do, to post the notice where products are stored/sold, and to forward the notice to device users, if possible. These customers include pharmacies, mail order companies, and distributors where the TRUE METRIX® meters are sold. Please refer to the Product Notice located at www.trividiahealth.com/E-5productnotice for more information.

You may continue to use the TRUE METRIX® Products. Products are not to be returned or replaced. This correction does not require removal of the Products from where they are used or sold. This labeling correction impacts the Owner’s Booklets/System Instructions for Use that accompany the meters at purchase, as well as the online labeling and help guides located on Trividia Health’s website. Trividia Health will notify users of additional mitigation strategies as needed.

Trividia Health has notified the U.S. Food and Drug Administration (FDA) of this action.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online: www.fda.gov/medwatch/report.htm

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

Patient safety is our top priority, and we apologize for any inconvenience this correction may cause you.

About Trividia Health

Trividia Health, Inc., is a global health and wellness company based in Fort Lauderdale, Florida and a leading developer, manufacturer and marketer of advanced performance products for people with diabetes. With products sold under TRUE and store brand labels, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.

Contacts

Annmarie Ramos
Media Contact
(800) 342-7226, ext. 3190

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Dems corner GOP on Trump's 'rank corruption' as public sours

Dems corner GOP on Trump's 'rank corruption' as public sours

On Monday it was revealed that President Donald Trump would drop his $10 billion lawsuit against the IRS in exchange for a $1.776 billion settlement that would
Share
Alternet2026/05/20 04:33
Sen. Warren launches a probe into the OCC, accusing the Trump administration of illegally granting “national trust” bank charters

Sen. Warren launches a probe into the OCC, accusing the Trump administration of illegally granting “national trust” bank charters

Senator Elizabeth Warren is challenging the Trump administration and “big tech” once again, this time accusing crypto companies like Stripe and Coinbase of bypassing
Share
Cryptopolitan2026/05/20 04:30
CME Group to launch Solana and XRP futures options in October

CME Group to launch Solana and XRP futures options in October

The post CME Group to launch Solana and XRP futures options in October appeared on BitcoinEthereumNews.com. CME Group is preparing to launch options on SOL and XRP futures next month, giving traders new ways to manage exposure to the two assets.  The contracts are set to go live on October 13, pending regulatory approval, and will come in both standard and micro sizes with expiries offered daily, monthly and quarterly. The new listings mark a major step for CME, which first brought bitcoin futures to market in 2017 and added ether contracts in 2021. Solana and XRP futures have quickly gained traction since their debut earlier this year. CME says more than 540,000 Solana contracts (worth about $22.3 billion), and 370,000 XRP contracts (worth $16.2 billion), have already been traded. Both products hit record trading activity and open interest in August. Market makers including Cumberland and FalconX plan to support the new contracts, arguing that institutional investors want hedging tools beyond bitcoin and ether. CME’s move also highlights the growing demand for regulated ways to access a broader set of digital assets. The launch, which still needs the green light from regulators, follows the end of XRP’s years-long legal fight with the US Securities and Exchange Commission. A federal court ruling in 2023 found that institutional sales of XRP violated securities laws, but programmatic exchange sales did not. The case officially closed in August 2025 after Ripple agreed to pay a $125 million fine, removing one of the biggest uncertainties hanging over the token. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/cme-group-solana-xrp-futures
Share
BitcoinEthereumNews2025/09/17 23:55

No Chart Skills? Still Profit

No Chart Skills? Still ProfitNo Chart Skills? Still Profit

Copy top traders in 3s with auto trading!